Oct 6, 2020

Stem cells for dry AMD with GA show promise in early study

October 1, 2020
Michelle Dalton, ELS
Patients underwent short-course, perioperative systemic immunosuppression prior to the procedure

This article was reviewed by Christopher D. Riemann, MD

Subretinal transplantation of human embryonic stem cells-derived retinal pigment epithelial (RPE) cells in patients with age-related macular degeneration (AMD) and geographic atrophy (GA) appears well-tolerated, according to Christopher D. Riemann, MD, of Cincinnati Eye Institute and the University of Cincinnati in Ohio.

During the Association for Research in Vision and Ophthalmology virtual annual meeting, he presented interim results of phase I/IIa trial investigating OpRegen for the treatment of dry AMD with GA (NCT02286089).

OpRegen is administered as a cell suspension, initially in a balanced salt solution but now in a thaw-and-inject formulation using CryoStor 5.

The US Food and Drug Administration has already granted OpRegen fast track designation, Riemann said…..

Read more: https://www.ophthalmologytimes.com/view/stem-cells-dry-amd-ga-show-promise-early-study?fbclid=IwAR2Mq5yB_tRpxiL2wYOQfaGQWbyTxzFEfHr-zajIO0mF350UdbwCpq8ZP0A

Source: Ophthalmology Times

Newsletter Sign-up

  • This field is for validation purposes and should be left unchanged.